Geometry.Net - the online learning center
Home  - Basic_G - Graft Vs Host Disease Bookstore
Page 1     1-20 of 92    1  | 2  | 3  | 4  | 5  | Next 20
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

         Graft Vs Host Disease:     more books (19)
  1. Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (Hematology) by Steven J. Burakoff, 1990-07
  2. Graft vs. Host Disease, Third Edition
  3. Graft-vs.-Host Disease: An entry from Gale's <i>Gale Encyclopedia of Medicine, 3rd ed.</i> by J., MD Polsdorfer, 2006
  4. Gale Encyclopedia of Cancer: Graft-vs.-host disease by M.S. Jill Granger, 2002-01-01
  5. Immunosuppressive Tx may get boost from adjunctive use of ECP. (Promising for Graft-vs.-Host Disease).(extracorporeal photophoresis ): An article from: Skin & Allergy News by Mitchel L. Zoler, 2003-07-01
  6. Gale Encyclopedia of Medicine: Graft-vs.-host disease by J. Ricker Polsdorfer MD, 2002-01-01
  7. Graft-vs.-host disease: An entry from Thomson Gale's <i>Gale Encyclopedia of Cancer, 2nd ed.</i> by J., M.D. Polsdorfer, Jill, M.S. Granger, 2006
  8. Graft vs. Host Disease, Third Edition by James Ferrara, 1980
  9. Chronic Graft Versus Host Disease: Interdisciplinary Management
  10. Graft-Versus-host Disease (Medical Intelligence Unit) by Ph.D., M.D. Nelson J. Chao, 1999-03-15
  11. Talking Points in Dermatology - I (New Clinical Applications: Dermatology) (No. 1)
  12. Practical Hematopoietic Stem Cell Transplantation
  13. Clinical and Diagnostic Pathology of Graft-versus-Host Disease by Berno Heymer, 2002-05-03
  14. Clinical evidence of autologous graft versus tumor effect.(Report): An article from: American Journal of Immunology by Luis F. Porrata, 2009-01-01

1. Immunologic Diseases -- Graft Vs Host Disease
Conversely, the transplanted immune cells can attack the tissues of the recipient,a potentially lifethreatening reaction called graft-vs-host disease.
50 YEARS NIAID HOMEPAGE INFECTIOUS DISEASES IMMUNOLOGIC DISEASES AIDS ... NIH HOMEPAGE The Immune System's Response to Transplants W hen tissue or organs from one person are transplanted into another, the recipient's immune system tries to get rid of this nonself tissue, a process called rejection. Conversely, the transplanted immune cells can attack the tissues of the recipient, a potentially life-threatening reaction called graft-vs-host disease. In 1980 three NIAID-supported scientists won the Nobel Prize in Physiology or Medicine for a discovery that revolutionized organ transplants. Tissue typing The researchers discovered a genetically determined group of cell and tissue "markers" called HLA antigens.
Basic scientific research increases our understanding of the immune system's response to transplants. These, they found, were different in each person producing a biochemical profile as unique as a fingerprint. Today this work is the basis for typing tissues to determine compatibility for organ and tissue transplants. The more alike are the donor's and recipient's HLA markers, the better the chance that the recipient's immune system will not reject the foreign tissue. NIAID-sponsored scientists also:
  • developed a tissue-typing technique that made possible the first bone marrow transplant between people other than identical twins.

2. DS 01-04 -Gastrointestinal Graft Vs Host Disease - Compassionate Use Of Oral Bec
Roswell Park Cancer Institute Compassionate Use of Oral BeclomethasoneDipropionate for Treatment of Gastrointestinal graft vs host disease.

3. Graft Vs Host Disease
graft vs host disease Companies with products addressing GVHD. Company Rankings,Symbol, Product, Development Stage. Abgenix, ABGX, ABXCBL, Phase III.
Graft vs Host Disease
Companies with products addressing GVHD. Company Rankings Symbol Product Development Stage
Abgenix ABGX ABX-CBL Phase III Protein Design Labs PDLI Zenapax Phase II Medimmune MEDI MEDI-507 Phase I/II ABX-CBL a monoclonal antibody produced with ABGX's Xenomouse GVHD most acute in bone marrow transplants current therapy includes steroids and horse antibody ATG - anti-thymocyte globulin from horses ABX-CBL intended to avoid steroid resistance CBL antigen on T cells, B cells and natural killer cells ABX-CBL targets only these cells immune suppression less than conventional therapy long term survival should be greater Medi-507 anti-CD2 humanized monoclonal antibody (MAB) binds to CD2 receptor of T cells and NK cells inhibits immune response to transplanted tissue does not inhibit normal immune function intended for use in GvHD (graft vs host disease) GvHD develops in bone marrow and stem cell transplants transplanted cells attack recipient's tissues 70% mortality rates 30,000 bone marrow or stem cell transplants/year MEDI-507 has been granted orphan drug status by FDA benefits for developing drug with small patient pool Zenapax (daclizumab; SMART Anti-Tac Antibody)

4. Graft Vs Host Disease
Parker Hughes Cancer Center/ New Drug Effective Against Graft Versus Host DiseaseOffers Hope to Bone Marrow Transplant Recipients 831-01 ROSEVILLE, Minn.
Graft vs Host Disease
Immunoglobulin Mechanism in GVHD Elucidated LONDON (Reuters Health) 10-23-01 Intravenous immunoglobulin (IVIg) decreases the severity of acute graft-versus-host disease (GVHD) by inducing apoptosis of donor T cells, French researchers conclude after completing a series of animal experiments.
Dr. Blanche Bellon, and colleagues at INSERM in Paris, induced acute GVHD in rats, which were then given IVIg, F(ab')2 fragments, or no treatment. Seventy-two percent of the rats that did not receive IVIg or F(ab')2 fragments were dead within 20 days, they report in the September issue of the European Journal of Immunology. In contrast, only 39% of the IVIg-treated and 20% of the F(ab')-treated rats had died or had clinical symptoms of GVHD.
In further experiments, acute GVHD was induced by transferring cells from male rats to female rats. The investigators found that IVIg induced apoptosis of the allogeneic donor CD4+CD134+ Th1 cytokine-producing T cells and dramatically reduced 0X40 antigen on CD4+ cells, thereby preventing GVHD in the treated rats, according to the report.
"Our present observations provide a specific mechanism for immunomodulation of GVHD by IVIg and emphasize the role of normal immunoglobulins in alloantigen immune responsiveness that develops in both deleterious graft-versus-donor and beneficial graft-versus- leukemia reactions," Dr. Bellon and colleagues conclude.

5. Immunologic Diseases
Links to information on autoimmune diseases, graft versus host disease, hypersensitivity and immunologic Category Science Biology Immunology...... Membranoproliferative glomerulonephritis, microscopic U. of Utah Webpath.graft vs host disease Ctr. Graftvs.-Host Disease Med. Coll.
Immunologic Diseases
Back to previous level

6. Immunologic Diseases
graft vs host disease Quick clinical facts about Graftvs.-Host Disease- CHORUS; Control of Graft versus Host Disease - BioScience
search help staff
Immunologic Diseases
Patients and laypersons looking for guidance among the target sources of this collection of links are strongly advised to review the information retrieved with their professional health care provider. Alphabetical List of Diseases

Search PubMed at NCBI/NLM

7. Surgeons Net Web Directory - Home > Transplant Surgery > Graft Vs Host Disease
Home/ Transplant Surgery/ graft vs host disease/. Control of GraftVersus Host Disease from Frontiers in Bioscience. Graft Versus
Free Email Home Transplant Surgery/ Graft vs Host Disease/
We subscribe to the HONcode principles of the Health On the Net Foundation
Surgeons Net Ltd

Terms and Conditions
Advertising Policy ... Discussion
Last modified: August 29 2002 01:07:14.

8. McGill Department Of Physiology • Faculty And Staff >> Faculty And Staff Direct
The role of endotoxin in the pathogenesis of acute graftvs-host disease. Ingraft vs host disease, 2 nd ed. J. Ferrara, J. Deeg and S. Burakoff, Eds.
PostDocs Research Labs Affiliated Centres Available Positions Today's date:
Wayne Lapp, Faculty Member Department of Physiology
McGill University
McIntyre Medical Sciences Building,
Room 1106
3655 Promenade Sir William Osler
Research Area: Physiology of the Immune System
Research Description:
Our laboratory has been interested in graft-vs-host disease (GVHD), a disease which often appears after bone marrow transplantation. We are investigating the molecular and cellular mechanisms responsible for GVHD induced pathological lesions and immune suppression. Experimentally induced GVHD is used to study immune regulation and it is also being used as a model to study various autoimmune diseases such as lupus and inflammatory bowel disease. Education: Ph.D., McGill Recent Publications: Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS.
IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma.
J Immunol. 1996 Oct 1;157(7):2851-6.

9. - Linking Patients To Medical Research: Results
10. Recruiting, Improved Methods of Cell Selection for Bone Marrow TransplantAlternatives Conditions graft vs host disease; Healthy; Lymphopenia. 11. Transplantat

10. - Linking Patients To Medical Research: Results
Study comparing ABXCBL (monoclonal antibody) versus Atgam in Patients with SteroidResistant Acute Graft versus Host Disease Condition graft vs host disease. Attack

11. Johns Hopkins Kimmel Cancer Center
Summary The principal goal of Dr. Hess’ laboratory is to elucidate the underlyingimmunobiological mechanisms associated with GVHD (graft vs host disease).

12. Graft-vs.-host And Graft-vs.-leukemia Reactions After Delayed
Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant. 1999;5(3):123-32. Unique Identifier : AIDSLINE MED/99320129
Johnson BD; Becker EE; Truitt RL; Department of Pediatrics, Medical College of Wisconsin, Milwaukee; 53226, USA. Abstract: Keywords: JOURNAL ARTICLE Animal Bone Marrow Transplantation CD4-Positive T-Lymphocytes/IMMUNOLOGY/TRANSPLANTATION CD8-Positive T-Lymphocytes/IMMUNOLOGY/TRANSPLANTATION Graft vs Host Disease/*IMMUNOLOGY/MORTALITY/THERAPY Graft vs Tumor Effect/*IMMUNOLOGY Histocompatibility Testing Infusions, Intravenous Leukemia, Experimental/IMMUNOLOGY/THERAPY Mice Mice, Inbred AKR Mice, Inbred C57BL Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocyte Subsets/IMMUNOLOGY/*TRANSPLANTATION Transplantation, Homologous
National Library of Medicine
. Reproduced under license with the National Library of Medicine, Bethesda, MD. Boehringer Ingelheim iMetrikus, Inc.

13. Graft-vs-host Disease And Immunologic Reconstitution In Bone
Antigens, CD3/ANALYSIS Antigens, Differentiation, TLymphocyte/ANALYSIS *Bone MarrowTransplantation CD4-CD8 Ratio graft vs host disease/*IMMUNOLOGY/THERAPY
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Graft-vs-host disease and immunologic reconstitution in bone marrow transplant recipients of related and unrelated grafts using total T-cell depletion (Meeting abstract). Exp Hematol; 20(6):707 1992. Unique Identifier : AIDSLINE ICDB/93688142
Hedderman A; Tricot G; Ballas CB; Leemhuis T; Grigsby S; Graves V; Hoffman R; Lebkowski J; Srour EF; Indiana Univ. Sch. of Medicine, Indianapolis, IN Abstract: Keywords: Antigens, CD/ANALYSIS Antigens, CD3/ANALYSIS Antigens, Differentiation, T-Lymphocyte/ANALYSIS *Bone Marrow Transplantation CD4-CD8 Ratio Graft vs Host Disease/*IMMUNOLOGY/THERAPY Human *Leukocyte Count Lymphocyte Depletion Receptors, IgG/ANALYSIS *T-Lymphocytes T-Lymphocytes, Suppressor-Effector ABSTRACT
National Library of Medicine
. Reproduced under license with the National Library of Medicine, Bethesda, MD. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim iMetrikus, Inc.

Similar pages PDFCellular and Cytokine Effectors of Acute Graft Versus Host vs Host Disease

15. Inflammatory Myopathy
Graftvs-host disease, 7 to 24 months post BMT. graft vs host disease(GVHD) + Myositis Onset 7 to 24 months post bone marrow transplant;

Search Index Links ... Patient Info
Inflammatory and Immune Myopathies
CK: Serum

: X-rays
Chondroitin sulfate C deficient



Focal myositis
Signal recognition particle
Vasculitis: Small Large vessel SPECIFIC IMMUNE OR INFLAMMATORY MYOPATHIES Polymyositis syndromes General aspects Classification Comparative features Collagen vascular disease Complement ... Quadriceps ; Other TRAPS Granulomatous Hemophagocytic lymphohistiocytosis Hereditary ... Multinodular polymyositis Necrotizing with Encephalopathy Paraneoplastic with Pipestem capillaries SRP antibodies ... MHC class I upregulation Skin lesions Erythema Gottron's papules Nailfold lesions From: Chinju, South Korea
Antibodies CK: Serum Electrodiagnostic Neoplasm associations ... Weakness Skin lesions

16. Non_myeloablative_Cord_Blood_transplant
Allogeneic Transplant In an allogeneic transplant, the two main complications thatcould arise are i. Host vs graft or graft failure ii. graft vs host disease.
18 February 2002 WORLD'S FIRST SUCCESSFUL POOLED UNRELATED CORD BLOOD TRANSPLANT WITH NON-MYELOABLATIVE APPROACH Singapore General Hospital's Department of Haematology's medical team lead by A/Prof Patrick Tan has successfully performed unrelated cord blood transplant for two adult patients using non-myeloablative approach and without high dose chemotherapy. The successful transplant for a 43-year-old man, Mr. Huang, suffering from acute myeloid leukaemia, which pooled two unrelated cord blood samples using non-myeloablative approach, is the first of its kind in the world. The cord blood samples were from local cord blood registry and from an American cord blood registry. He underwent the transplant on 12 December 2001. The other patient, Mr Slamet Sampoerno is a 40-year-old Indonesian man who had multiple myeloma. This is also the first known case of unrelated cord blood transplant using non-myeloablative approach performed for multiple myeloma. The transplant was performed on 28 November 2001. Allogeneic Transplant
In an allogeneic transplant, the two main complications that could arise are:

17. Entrez-PubMed
Abstract, CNS angiitis in graft vs host disease. Neurology. 2002 Dec24;59(12)19947. PMID 12499502 PubMed - indexed for MEDLINE.

18. Indexing Initiative Prototype
Female (check tag). Graft Survival (14). graft vs host disease (4). GranulocyteColonyStimulating Factor (7). Histocompatibility (11). Male (check tag).
link to PubMed:
Medline Citation: MEDLINE indexed MeSH expressions are displayed in the left column. MeSH expressions that concur with terms suggested by the Indexing Initiative prototype are displayed in red. The number in parenthesis indicates the prototype's rank order.
out of starred MeSH expressions are suggested by Indexing Initiative prototype.
out of starred MeSH expressions are suggested by Indexing Initiative prototype.
Indexed MeSH Expressions
Additional Suggested MeSH Expressions *Bone Marrow Transplantation (5) *Hematopoiesis (6) *Stem Cell Factor (1) Animal (check tag) Dogs (check tag) Female (check tag) Graft Survival (14) Graft vs Host Disease (4) Granulocyte Colony-Stimulating Factor (7) Histocompatibility (11) Male (check tag) Recombinant Proteins Time Factors
Bone Marrow (2) Whole-Body Irradiation (3) Monocytes (8) Hematopoietic Stem Cells (9) Radiation Chimera (10) Hematopoietic Stem Cell Transplantation (12) Neutrophils (13) Hematopoietic Cell Growth Factors (15) Lymphocytes (16) Transplantation, Homologous (17)

19. NewScreen(tm) - Frequently Asked Questions About Cord Blood Banking
higher survival rate, a higher quality of life after transplant and less frequenthospitalization due to fewer complications such as graft vs host disease (GHVD

About NewScreen
Cord Blood Banking Our clients
Important to save
Download instructions

Cord Blood Stem Cells
What is cord blood?

What are stem cells?

How are stem cells used in medicine?

What types of diseases are treated with stem cell transplantation?
What is Graft v. Host Disease (GVHD)?

What is Cord Blood? Cord blood (sometimes called placental blood or umbilical cord blood) is the blood that remains in the umbilical cord and placenta following birth. Like bone marrow, cord blood has been found to be a rich source of stem cells. The Harvard Health Letter (published in March 1997) named cord blood one of the top 10 medical advances of 1996. Return to Index What are stem cells? Stem cells are the building blocks of your blood and immune system and reside primarily in your bone marrow. There are three known sources of stem cells: Bone Marrow, Peripheral Blood (the blood that circulates throughout your body), and Umbilical Cord Blood. Stem Cells are the "mother cells" that lead to the production of all the various types of cells in the blood. Stem cells reproduce into: Red Blood Cells - which carry oxygen throughout the body White Blood Cells - which fight infection Platelets - which aid in clotting Return to Index How are stem cells used in medicine?

20. CML Discussion Area
off residual disease. However, this induces graft vs host diseaseor GVHD and efforts are ongoing to reduce this. The problem is

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

Page 1     1-20 of 92    1  | 2  | 3  | 4  | 5  | Next 20

free hit counter